Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Börnsen, Lars ^a   Christensen, Jeppe Romme ^a   Ratzer, Rikke ^a   Hedegaard, Chris ^a   Søndergaard, Helle B ^a   Krakauer, Martin ^a   Hesse, Dan ^a   Nielsen, Claus H ^a   Sorensen, Per S ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 27; INTERLEUKIN 4; MESSENGER RNA; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; INTERFERON;

ADULT; ARTICLE; B LYMPHOCYTE; BETA INTERFERON INDUCIBLE GENE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE DURATION; EX VIVO STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ANIMALIA;

ADULT; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; INTERLEUKIN-10; INTRACELLULAR SPACE; MALE; MONOCYTES; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; T-LYMPHOCYTE SUBSETS;

EID: 84929485704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118830     Document Type: Article

References (54)

1. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull. 2003; 61: 321-326. PMID: 12909302
2. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol. 2009; 65: 239-248. doi: 10.1002/ana.21640 PMID: 19334069
3. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005; 23: 683-747. PMID: 15771584
4. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005; 23: 307-336. PMID: 15771573
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39: 285-294. PMID: 8602746
6. Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology. 1997; 48: 1446-1448. PMID: 9153489
7. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest. 2008; 118: 1680-1690. doi: 10.1172/JCI33342 PMID: 18382764
8. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009; 183: 5418-5427. doi: 10.4049/jimmunol.0803227 PMID: 19783688
9. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, et al. IL-27 mediates the response to IFN-beta therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun. 2011; 25: 1170-1181. doi: 10.1016/j.bbi.2011.03.007 PMID: 21420486
10. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, et al. Type I interferon inhibits interleukin- 1 production and inflammasome activation. Immunity. 2011; 34: 213-223. doi: 10.1016/j.immuni. 2011.02.006 PMID: 21349431
11. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol. 2003; 170: 4776-4784. PMID: 12707359
12. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 2008; 28: 675-686. doi: 10.1016/j.immuni.2008.03.011 PMID: 18424188
13. Galligan CL, Pennell LM, Murooka TT, Baig E, Majchrzak-Kita B, Rahbar R, et al. Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitis. Mult Scler. 2010; 16: 1458-1473. doi: 10.1177/1352458510381259 PMID: 20935030
14. Martin-Saavedra FM, Flores N, Dorado B, Eguiluz C, Bravo B, Garcia-Merino A, et al. Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Mol Immunol. 2007; 44: 3597-3607. PMID: 17420051
15. Axtell RC, Raman C, Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011; 32: 272-277. doi: 10.1016/j.it.2011.03.008 PMID: 21530402
16. Yamaguchi KD, Ruderman DL, Croze E, Wagner TC, Velichko S, Reder AT, et al. IFN-beta-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008; 195: 116-120. doi: 10.1016/j.jneuroim.2007.12.007 PMID: 18279974
17. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 2006; 7: 522-531. PMID: 16837931
18. Hesse D, Krakauer M, Lund H, Sondergaard HB, Limborg SJ, Sorensen PS, et al. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol. 2011; 18: 266-272. doi: 10.1111/j.1468-1331.2010.03116.x PMID: 20561040
19. van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol. 2010; 67: 402-407. doi: 10.1001/archneurol.2010.21 PMID: 20142519
20. van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 2010; 75: 1228-1233. doi: 10.1212/WNL.0b013e3181f6c556 PMID: 20921509
21. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, Nielsen CH. Thelper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology. 2008; 125: 161-169. doi: 10.1111/j.1365-2567.2008.02837.x PMID: 18397264
22. Hesse D, Krakauer M, Lund H, Sondergaard HB, Langkilde A, Ryder LP, et al. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010; 74: 1455-1462. doi: 10.1212/WNL.0b013e3181dc1a94 PMID: 20439848
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408. PMID: 11846609
24. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol. 2009; 16: 1291-1298. doi: 10.1111/j.1468-1331.2009.02716.x PMID: 19558503
25. Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2007; 2: 2049-2056. PMID: 17853860
26. Zafranskaya M, Oschmann P, Engel R, Weishaupt A, van Noort JM, Jomaa H, et al. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology. 2007; 121: 29-39. PMID: 17239199
27. Hallal-Longo DE, Mirandola SR, Oliveira EC, Farias AS, Pereira FG, Metze IL, et al. Diminished myelinspecific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J Interferon Cytokine Res. 2007; 27: 865-873. PMID: 17970696
28. Hedegaard CJ, Krakauer M, Bendtzen K, Sorensen PS, Sellebjerg F, Nielsen CH. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clin Immunol. 2008; 129: 80-89. doi: 10.1016/j.clim.2008.06.007 PMID: 18653385
29. Kieseier BC The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs. 2011; 25: 491-502. doi: 10.2165/11591110-000000000-00000 PMID: 21649449
30. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E, Fernandez M, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009; 132: 3353-3365. doi: 10.1093/brain/awp228 PMID: 19741051
31. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology. 2012; 79: 531-537. doi: 10.1212/WNL.0b013e318259e123 PMID: 22573631
32. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995; 61: 27-34. PMID: 7560009
33. Rudick RA, Ransohoff RM, Peppler R, VanderBrug MS, Lehmann P, Alam J. Interferon beta induces interleukin- 10 expression: relevance to multiple sclerosis. Ann Neurol. 1996; 40: 618-627. PMID: 8871582
34. Navikas V, Link J, Palasik W, Soderstrom M, Fredrikson S, Olsson T, et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol. 1995; 41: 171-178. PMID: 7532318
35. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Cytokine changes during interferonbeta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol. 2007; 185: 168-174. PMID: 17328965
36. Carrieri PB, Provitera V, De RT, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol. 1998; 20: 373-382. PMID: 9736442
37. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998; 50: 1294-1300. PMID: 9595977
38. Calabresi PA, Tranquill LR, McFarland HF, Cowan EP. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J Neuroimmunol. 1998; 89: 198-205. PMID: 9726843
39. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler. 2008; 14: 622-630. doi: 10.1177/1352458507087136 PMID: 18424480
40. Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol. 2002; 51: 165-174. PMID: 11835372
41. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 1994; 44: 1523-1526. PMID: 8058164
42. Babaloo Z, Yeganeh RK, Farhoodi M, Baradaran B, Bonyadi M, Aghebati L. Increased IL-17A but decreased IL-27 serum levels in patients with multiple sclerosis. Iran J Immunol. 2013; 10: 47-54. doi: IJIv10i1A6 PMID: 23502338
43. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family f cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29: 71-109. doi: 10.1146/annurevimmunol- 031210-101312 PMID: 21166540
44. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin- 10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. 2006; 117: 433-442. PMID: 16556256
45. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010; 21: 331-344. doi: 10.1016/j.cytogfr.2010.09.002 PMID: 21115385
46. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin- 10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med. 2010; 16: 452-459. doi: 10.1038/nm.2106 PMID: 20208540
47. Verreck FA, de BT, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, et al. Human IL- 23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 2004; 101: 4560-4565. PMID: 15070757
48. de Waal MR, Haanen J, Spits H, Roncarolo MG, te VA, Figdor C, Johnson K, et al. Interleukin 10 (IL- 10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen- presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991; 174: 915-924. PMID: 1655948
49. Nielsen CH, Galdiers MP, Hedegaard CJ, Leslie RG. The self-antigen, thyroglobulin, induces antigenexperienced CD4+ T cells from healthy donors to proliferate and promote production of the regulatory cytokine, interleukin-10, by monocytes. Immunology. 2010; 129: 291-299. doi: 10.1111/j.1365-2567. 2009.03183.x PMID: 19845795
50. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011; 585: 3611-3618. doi: 10.1016/j.febslet.2011. 04.025 PMID: 21513711
51. Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta. 2011; 1812: 246-251. doi: 10.1016/j.bbadis.2010.05.012 PMID: 20600875
52. Schulz EG, Mariani L, Radbruch A, Hofer T. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12. Immunity. 2009; 30: 673-683. doi: 10.1016/j. immuni.2009.03.013 PMID: 19409816
53. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol. 2001; 2: 378-386. PMID: 11331912
54. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007; 25: 821-852. PMID: 17201677